Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

Lifespan Vision Ventures Leads Violet Therapeutics’ $4.75M Seed Extension Financing

NORWALK, Conn., May 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused…

54 minutes ago

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of…

54 minutes ago

Chandigarh University Biotechnology Scientists Faculty Secure Rs 1.16 Crore Government Grants from ICMR and ANRF for Mustard Yield and Diabetic Kidney Disease Research

Chandigarh University Scientist to Boost Mustard Productivity through Microbe-Based Research with Rs 60 Lakh PM-ECRG…

54 minutes ago

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific today announced a…

54 minutes ago

ADGM Strengthens Position as MEASA’s Leading IFC With 57% Growth in AUM, over 13,000 Active Licences in Q1 2026

ABU DHABI, UAE, May 18, 2026 /PRNewswire/ -- ADGM, the international financial centre of Abu Dhabi,…

4 hours ago

NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 18, 2026…

4 hours ago